BiotechTube
Lyra Therapeutics

Lyra Therapeutics

LYRA
United States

Lyra Therapeutics is focused on transforming the treatment paradigm for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million people in the United States. The company leverages its proprietary drug-eluting nasal mesh technology to deliver sustained, localized therapy directly to the disease site, aiming to break the cycle of ineffective medical management. With its lead candidate, LYR-210, in Phase 3 development and a second candidate, LYR-220, in its pipeline, Lyra is positioned to address a large, underserved market. The company is publicly traded and led by an experienced team of drug developers.

lyratherapeutics.com

LYRA · Stock Price

USD 0.49-7.14 (-93.58%)
Market Cap: $870K

Historical price data

AI Company Overview

Lyra Therapeutics is focused on transforming the treatment paradigm for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million people in the United States. The company leverages its proprietary drug-eluting nasal mesh technology to deliver sustained, localized therapy directly to the disease site, aiming to break the cycle of ineffective medical management. With its lead candidate, LYR-210, in Phase 3 development and a second candidate, LYR-220, in its pipeline, Lyra is positioned to address a large, underserved market. The company is publicly traded and led by an experienced team of drug developers.

Ear, Nose, and Throat (ENT)Inflammatory Diseases

Technology Platform

A proprietary drug-eluting, bioabsorbable nasal mesh designed for sustained, localized delivery of anti-inflammatory medication directly to the sinonasal passages for up to six months from a single administration.

Pipeline

5
5 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
LYR-210 + Sham procedure controlChronic SinusitisPhase 3
LYR-210 + Sham procedure controlChronic SinusitisPhase 3
LYR-210Chronic SinusitisPhase 2
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 an...Chronic SinusitisPhase 2
480 Mometasone Furoate Sinus Drug DepotChronic SinusitisPhase 1

Opportunities

The primary opportunity is addressing the vast unmet need in the 14-million-patient U.S.
CRS market with a first-in-class, long-acting localized therapy.
Success with LYR-210 could establish a new treatment paradigm and pave the way for LYR-220, which targets a different anatomical subset of patients, further expanding market potential.

Risk Factors

Key risks include clinical trial failure in Phase 3, regulatory rejection, challenges in building a commercial sales force and securing reimbursement, and the need for additional financing.
The company's future is singularly dependent on the success of LYR-210.

Competitive Landscape

Lyra competes with standard-of-care medications, sinus surgery, and systemic biologics like Dupixent. Its main differentiation is the localized, six-month sustained drug delivery from a single, bioabsorbable implant, aiming for superior efficacy, convenience, and a favorable safety profile compared to existing options.

More companies in Drug Delivery & Formulation →More companies in United States →